Evaluation of cisplatin dose intensity: Current status and future prospects

D. R. Gandara, E. A. Perez, W. A. Phillips, H. J. Lawrence, M. DeGregorio

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Cisplatin dose intensity is a potentially important concept in the chemotherapeutic management of several human malignancies. In vitro studies have demonstrated steep dose-response relationships in a variety of tumor types. Although previous clinical trials have also suggested the importance of cisplatin dose, renal insufficiency has limited exploration of more dose-intensive regimens. Recently, therapeutic strategies such as hypertonic saline have allowed dose escalation to the level of 200 mg/m2/28 day cycle, or 50 mg/m2/week as standardized for dose intensity analysis. In this review, we summarize the rationale for investigation of cisplatin dose intensity, pertinent pharmacokinetics, and potential methods of dose escalation. Clinical data are presented regarding both efficacy and newly recognized non-renal toxicities of high-dose cisplatin. We describe the results of a pharmacokinetically designed schedule of high-dose cisplatin in hypertonic saline, administering a divided dose of 100 mg/m2 on days 1 and 8 of each 28-day cycle. This regimen has resulted in high response rates and encouraging survival times in non-small cell lung cancer, and is currently being investigated in several different tumor types. Compared to other dose-intensive regimens, this day 1 and 8 schedule is relatively well-tolerated, with a toxicity pattern not substantially different from standard-dose cisplatin. Since non-renal toxicities such as peripheral neuropathy continue to limit cumulative cisplatin dose, other methods of increasing dose intensity are of considerable interest. We present the rationale and current trials utilizing chemoprotective or <<rescue>> agents as a means of maximizing cisplatin dose intensity and minimizing the toxicity of this agent.

Original languageEnglish (US)
Pages (from-to)1121-1128
Number of pages8
JournalAnticancer Research
Volume9
Issue number4
StatePublished - 1989
Externally publishedYes

Fingerprint

Cisplatin
Appointments and Schedules
Neoplasms
Peripheral Nervous System Diseases
Non-Small Cell Lung Carcinoma
Renal Insufficiency
Pharmacokinetics
Clinical Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gandara, D. R., Perez, E. A., Phillips, W. A., Lawrence, H. J., & DeGregorio, M. (1989). Evaluation of cisplatin dose intensity: Current status and future prospects. Anticancer Research, 9(4), 1121-1128.

Evaluation of cisplatin dose intensity : Current status and future prospects. / Gandara, D. R.; Perez, E. A.; Phillips, W. A.; Lawrence, H. J.; DeGregorio, M.

In: Anticancer Research, Vol. 9, No. 4, 1989, p. 1121-1128.

Research output: Contribution to journalArticle

Gandara, DR, Perez, EA, Phillips, WA, Lawrence, HJ & DeGregorio, M 1989, 'Evaluation of cisplatin dose intensity: Current status and future prospects', Anticancer Research, vol. 9, no. 4, pp. 1121-1128.
Gandara DR, Perez EA, Phillips WA, Lawrence HJ, DeGregorio M. Evaluation of cisplatin dose intensity: Current status and future prospects. Anticancer Research. 1989;9(4):1121-1128.
Gandara, D. R. ; Perez, E. A. ; Phillips, W. A. ; Lawrence, H. J. ; DeGregorio, M. / Evaluation of cisplatin dose intensity : Current status and future prospects. In: Anticancer Research. 1989 ; Vol. 9, No. 4. pp. 1121-1128.
@article{b8d1b3c34884443bb526ffcbedc5a0e7,
title = "Evaluation of cisplatin dose intensity: Current status and future prospects",
abstract = "Cisplatin dose intensity is a potentially important concept in the chemotherapeutic management of several human malignancies. In vitro studies have demonstrated steep dose-response relationships in a variety of tumor types. Although previous clinical trials have also suggested the importance of cisplatin dose, renal insufficiency has limited exploration of more dose-intensive regimens. Recently, therapeutic strategies such as hypertonic saline have allowed dose escalation to the level of 200 mg/m2/28 day cycle, or 50 mg/m2/week as standardized for dose intensity analysis. In this review, we summarize the rationale for investigation of cisplatin dose intensity, pertinent pharmacokinetics, and potential methods of dose escalation. Clinical data are presented regarding both efficacy and newly recognized non-renal toxicities of high-dose cisplatin. We describe the results of a pharmacokinetically designed schedule of high-dose cisplatin in hypertonic saline, administering a divided dose of 100 mg/m2 on days 1 and 8 of each 28-day cycle. This regimen has resulted in high response rates and encouraging survival times in non-small cell lung cancer, and is currently being investigated in several different tumor types. Compared to other dose-intensive regimens, this day 1 and 8 schedule is relatively well-tolerated, with a toxicity pattern not substantially different from standard-dose cisplatin. Since non-renal toxicities such as peripheral neuropathy continue to limit cumulative cisplatin dose, other methods of increasing dose intensity are of considerable interest. We present the rationale and current trials utilizing chemoprotective or <> agents as a means of maximizing cisplatin dose intensity and minimizing the toxicity of this agent.",
author = "Gandara, {D. R.} and Perez, {E. A.} and Phillips, {W. A.} and Lawrence, {H. J.} and M. DeGregorio",
year = "1989",
language = "English (US)",
volume = "9",
pages = "1121--1128",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Evaluation of cisplatin dose intensity

T2 - Current status and future prospects

AU - Gandara, D. R.

AU - Perez, E. A.

AU - Phillips, W. A.

AU - Lawrence, H. J.

AU - DeGregorio, M.

PY - 1989

Y1 - 1989

N2 - Cisplatin dose intensity is a potentially important concept in the chemotherapeutic management of several human malignancies. In vitro studies have demonstrated steep dose-response relationships in a variety of tumor types. Although previous clinical trials have also suggested the importance of cisplatin dose, renal insufficiency has limited exploration of more dose-intensive regimens. Recently, therapeutic strategies such as hypertonic saline have allowed dose escalation to the level of 200 mg/m2/28 day cycle, or 50 mg/m2/week as standardized for dose intensity analysis. In this review, we summarize the rationale for investigation of cisplatin dose intensity, pertinent pharmacokinetics, and potential methods of dose escalation. Clinical data are presented regarding both efficacy and newly recognized non-renal toxicities of high-dose cisplatin. We describe the results of a pharmacokinetically designed schedule of high-dose cisplatin in hypertonic saline, administering a divided dose of 100 mg/m2 on days 1 and 8 of each 28-day cycle. This regimen has resulted in high response rates and encouraging survival times in non-small cell lung cancer, and is currently being investigated in several different tumor types. Compared to other dose-intensive regimens, this day 1 and 8 schedule is relatively well-tolerated, with a toxicity pattern not substantially different from standard-dose cisplatin. Since non-renal toxicities such as peripheral neuropathy continue to limit cumulative cisplatin dose, other methods of increasing dose intensity are of considerable interest. We present the rationale and current trials utilizing chemoprotective or <> agents as a means of maximizing cisplatin dose intensity and minimizing the toxicity of this agent.

AB - Cisplatin dose intensity is a potentially important concept in the chemotherapeutic management of several human malignancies. In vitro studies have demonstrated steep dose-response relationships in a variety of tumor types. Although previous clinical trials have also suggested the importance of cisplatin dose, renal insufficiency has limited exploration of more dose-intensive regimens. Recently, therapeutic strategies such as hypertonic saline have allowed dose escalation to the level of 200 mg/m2/28 day cycle, or 50 mg/m2/week as standardized for dose intensity analysis. In this review, we summarize the rationale for investigation of cisplatin dose intensity, pertinent pharmacokinetics, and potential methods of dose escalation. Clinical data are presented regarding both efficacy and newly recognized non-renal toxicities of high-dose cisplatin. We describe the results of a pharmacokinetically designed schedule of high-dose cisplatin in hypertonic saline, administering a divided dose of 100 mg/m2 on days 1 and 8 of each 28-day cycle. This regimen has resulted in high response rates and encouraging survival times in non-small cell lung cancer, and is currently being investigated in several different tumor types. Compared to other dose-intensive regimens, this day 1 and 8 schedule is relatively well-tolerated, with a toxicity pattern not substantially different from standard-dose cisplatin. Since non-renal toxicities such as peripheral neuropathy continue to limit cumulative cisplatin dose, other methods of increasing dose intensity are of considerable interest. We present the rationale and current trials utilizing chemoprotective or <> agents as a means of maximizing cisplatin dose intensity and minimizing the toxicity of this agent.

UR - http://www.scopus.com/inward/record.url?scp=0024426986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024426986&partnerID=8YFLogxK

M3 - Article

C2 - 2683991

AN - SCOPUS:0024426986

VL - 9

SP - 1121

EP - 1128

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -